Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study
Study sponsor: Emergent BioSolutions
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2020-03-05Actual
Enrollment · participants210Actual
Source updated2025-09-08Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.